FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
A new analysis points to aging patients, rising med-spa volume, and next-generation HA and biostimulatory formulas as drivers behind the projected jump to an $8.45B global fillers market.